2013
Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
Moore K, Bendell J, Olszanski A, Desai M, Jansen M, Scheyer R, Senaldi G, LoRusso P. Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2519-2519. DOI: 10.1200/jco.2013.31.15_suppl.2519.Peer-Reviewed Original ResearchAdvanced solid tumorsYear old femaleAnti-tumor activitySolid tumorsMonoclonal antibodiesDose level cohortsDose-expansion studyDose-escalation studyBi-exponential dispositionEpidermal growth factor-like growth factorEGF family membersTumor growth inhibitionFactor-like growth factorG1 toxicityProgressive diseaseAnti-angiogenesis activityStandard treatmentPatientsRelated AEsExtension phasePhase IGrowth factorLevel cohortsWeeksWeeklyA phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
Kristeleit R, Shapiro G, LoRusso P, Infante J, Flynn M, Patel M, Tolaney S, Hilton J, Calvert A, Giordano H, Isaacson J, Borrow J, Allen A, Jaw-Tsai S, Burris H. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2585-2585. DOI: 10.1200/jco.2013.31.15_suppl.2585.Peer-Reviewed Original ResearchAdvanced solid tumorsOral rucaparibStable diseaseTrough levelsSolid tumorsIntra-patient dose escalationOverall disease control rateTreatment-related adverse eventsOral small-molecule inhibitorDose-proportional PKDurable stable diseaseLow interpatient variabilityPhase 2 doseDisease control rateDose-escalation designDose cohortsBID dosingAdverse eventsObjective responsePK assessmentDose escalationEscalation designControl rateQD dosingStandard treatment
2001
Analysis of skeletal-related events in breast cancer and response to therapy
LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Seminars In Oncology 2001, 28: 22-27. PMID: 11544572, DOI: 10.1016/s0093-7754(01)90228-3.Peer-Reviewed Original ResearchConceptsBone metastasesSkeletal morbiditySkeletal complicationsSkeletal related eventsTreatment of choiceBone painIntravenous pamidronateBisphosphonate treatmentSignificant morbidityCancer patientsPotent bisphosphonateStandard treatmentBone resorptionSurrogate markerClinical trialsCommon siteMetastatic cancerBreast cancerMorbidityMetastasisPatientsLife measurementsTherapyComplicationsPamidronate